Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-609-3001 Open-Label Extension in Hunter Syndrome
2023-504127-90-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Feb 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of idursulfase in mucopolysaccharidosis type 2, sponsored by Takeda. Primary endpoint: Safety of intrathecal idursulfase-IT administration. Planned start Feb 2024; status: authorised.
02
Drugs
idursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2023-504127-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504127-90-00.